Literature DB >> 23148617

Clinical imaging of tumor angiogenesis.

Neel Patel1, Adrian L Harris, Fergus V Gleeson, Katherine A Vallis.   

Abstract

Angiogenesis is an integral part of tumor growth and invasion. This has led to the emergence of several antiangiogenic therapies and stimulated efforts to accurately evaluate the extent of angiogenesis before and in response to anticancer treatment. The most commonly used approach has been the assessment of new vessel formation in histological samples. However, it is becoming apparent that this is insufficient for a full understanding of tumor physiology and for in vivo guidance of cancer management. Imaging has the potential to provide noninvasive and repeatable assessment of the angiogenic process. Imaging approaches use a variety of modalities and are aimed at either assessment of the functional integrity of tumor vasculature or assessment of its molecular status. This review summarizes the aims and methods of clinical tumor angiogenesis imaging, including present technologies and ones that will be developed within the next 5-10 years.

Entities:  

Mesh:

Year:  2012        PMID: 23148617     DOI: 10.2217/fon.12.136

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  9 in total

1.  High and low frequency subharmonic imaging of angiogenesis in a murine breast cancer model.

Authors:  Manasi Dahibawkar; Mark A Forsberg; Aditi Gupta; Samantha Jaffe; Kelly Dulin; John R Eisenbrey; Valgerdur G Halldorsdottir; Anya I Forsberg; Jaydev K Dave; Andrew Marshall; Priscilla Machado; Traci B Fox; Ji-Bin Liu; Flemming Forsberg
Journal:  Ultrasonics       Date:  2015-05-05       Impact factor: 2.890

2.  The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.

Authors:  Flemming Forsberg; Raymond J Ro; Andrew Marshall; Ji-Bin Liu; See-Ying Chiou; Daniel A Merton; Priscilla Machado; Adam P Dicker; Levon N Nazarian
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

3.  Comparison of tumor neovasculature-targeted paramagnetic nanoliposomes for MRI in mice xenograft models.

Authors:  Q-H Xu; J-Y Shi; J Zhang; Y-F Sun; A H Chang; Y-M Zhao; W-J Cai; D Liu; C-C Zhou; L-H Fan; B Su
Journal:  Clin Transl Oncol       Date:  2013-08-27       Impact factor: 3.405

4.  Grating-based phase-contrast imaging of tumor angiogenesis in lung metastases.

Authors:  Huimin Lin; Binquan Kou; Xiangting Li; Yujie Wang; Bei Ding; Chen Shi; Huanhuan Liu; Rongbiao Tang; Jianqi Sun; Fuhua Yan; Huan Zhang
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

5.  The value of dynamic contrast-enhanced MRI in characterizing complex ovarian tumors.

Authors:  Hai-Ming Li; Jin-Wei Qiang; Feng-Hua Ma; Shu-Hui Zhao
Journal:  J Ovarian Res       Date:  2017-01-14       Impact factor: 4.234

6.  Usefulness of Hounsfield Units and the Serum Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Patients with Breast Cancer.

Authors:  Seok Hahn; Kwang-Min Kim; Min-Ju Kim; Hyang-Suk Choi; Hany Noh; In-Jeong Cho; Seung-Taek Lim; Jong-In Lee; Airi Han
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

Review 7.  Predicting tumour response.

Authors:  Samuel D Kyle; W Phillip Law; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

8.  Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.

Authors:  Cathy C Zhang; Zhengming Yan; Anand Giddabasappa; Patrick B Lappin; Cory L Painter; Qin Zhang; Gang Li; James Goodman; Brett Simmons; Bernadette Pascual; Joseph Lee; Ted Levkoff; Tim Nichols; Zhiyong Xie
Journal:  Cancer Med       Date:  2014-02-27       Impact factor: 4.452

9.  The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats.

Authors:  Nan Li; Bin Chen; Run Lin; Ni Liu; Hai-Tao Dai; Ke-Yu Tang; Jian-Yong Yang; Yong-Hui Huang
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-01       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.